HK1080364B - 具有改进的生物利用率的液体药物口服药物剂型 - Google Patents

具有改进的生物利用率的液体药物口服药物剂型 Download PDF

Info

Publication number
HK1080364B
HK1080364B HK06100214.4A HK06100214A HK1080364B HK 1080364 B HK1080364 B HK 1080364B HK 06100214 A HK06100214 A HK 06100214A HK 1080364 B HK1080364 B HK 1080364B
Authority
HK
Hong Kong
Prior art keywords
nitroxide
ester
methyl
acid
alpha
Prior art date
Application number
HK06100214.4A
Other languages
English (en)
Chinese (zh)
Other versions
HK1080364A1 (en
Inventor
Piero Del Soldato
Giancarlo Santus
Cristina Macelloni
Original Assignee
Nicox S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox S.A. filed Critical Nicox S.A.
Publication of HK1080364A1 publication Critical patent/HK1080364A1/xx
Publication of HK1080364B publication Critical patent/HK1080364B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06100214.4A 2002-06-25 2003-06-20 具有改进的生物利用率的液体药物口服药物剂型 HK1080364B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2002A001392 2002-06-25
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
PCT/EP2003/006496 WO2004000273A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability

Publications (2)

Publication Number Publication Date
HK1080364A1 HK1080364A1 (en) 2006-04-28
HK1080364B true HK1080364B (zh) 2008-02-01

Family

ID=11450079

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100214.4A HK1080364B (zh) 2002-06-25 2003-06-20 具有改进的生物利用率的液体药物口服药物剂型

Country Status (23)

Country Link
US (1) US20060171969A1 (https=)
EP (1) EP1526839B1 (https=)
JP (1) JP2005530835A (https=)
KR (1) KR20060076136A (https=)
CN (1) CN1319518C (https=)
AT (1) ATE356612T1 (https=)
AU (1) AU2003246564B2 (https=)
CA (1) CA2491152A1 (https=)
DE (1) DE60312523T2 (https=)
DK (1) DK1526839T3 (https=)
ES (1) ES2285182T3 (https=)
HK (1) HK1080364B (https=)
IL (1) IL165601A0 (https=)
IT (1) ITMI20021392A1 (https=)
MX (1) MXPA04012852A (https=)
NO (1) NO20050347L (https=)
NZ (1) NZ537204A (https=)
PL (1) PL206599B1 (https=)
PT (1) PT1526839E (https=)
RU (1) RU2323003C2 (https=)
SI (1) SI1526839T1 (https=)
WO (1) WO2004000273A1 (https=)
ZA (1) ZA200410109B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
US20030148818A1 (en) * 2002-01-18 2003-08-07 Myrhum Mark C. Golf club woods with wood club head having a selectable center of gravity and a selectable shaft
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
WO2003103602A2 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
PL1879466T5 (pl) * 2005-03-04 2016-07-29 Dsm Ip Assets Bv Spożywcza cząsteczkowa kompozycja lipidowa
US20080260816A1 (en) * 2005-09-16 2008-10-23 Bengt Herslof Particulate Lipid Pharmaceutical Composition
US20080293781A1 (en) 2005-11-23 2008-11-27 Alberto Gasco Salicylic Acid Derivatives
EP2786749A1 (en) * 2006-02-03 2014-10-08 Nicox S.A. Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
MX2009011493A (es) * 2007-04-25 2009-11-09 Teva Pharma Complejo de excipiente farmaceutico.
WO2009149053A2 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Naproxcinod process and solid dispersion
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
CN102964250A (zh) * 2012-11-19 2013-03-13 吉林大学 氟比洛芬丁香酚酯药用化合物及其制剂和制备方法
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
CN105188677A (zh) 2013-03-13 2015-12-23 特瑞斯制药股份有限公司 苯佐那酯调释固体片剂和胶囊剂
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US12520867B2 (en) 2019-12-09 2026-01-13 Nicoventures Trading Limited Buffered oral compositions
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
MX2022007085A (es) * 2019-12-09 2022-08-19 Nicoventures Trading Ltd Nanoemulsion para uso oral.
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
MX2023015529A (es) 2021-06-25 2024-03-05 Nicoventures Trading Ltd Productos orales y metodo de fabricacion.
IL312564A (en) 2021-11-05 2024-07-01 Cinclus Pharma Holding Ab Publ Polymorphs of the hydrochloride salt of linfarezan glurate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5266615A (en) * 1975-11-29 1977-06-02 Sawai Seiyaku Kk Manufacturing of solidified oily liquid substance
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
JPS58213073A (ja) * 1982-06-07 1983-12-10 Masatoshi Yamada 油状物質の固形化法
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
JP2000016934A (ja) * 1998-06-30 2000-01-18 Eisai Co Ltd テプレノンを含有した錠剤
EP2127642A3 (en) * 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
EP1140027B1 (en) * 1998-12-23 2005-10-12 Alza Corporation Dosage forms comprising porous particles
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition

Also Published As

Publication number Publication date
WO2004000273A1 (en) 2003-12-31
HK1080364A1 (en) 2006-04-28
ATE356612T1 (de) 2007-04-15
MXPA04012852A (es) 2005-06-08
RU2323003C2 (ru) 2008-04-27
EP1526839B1 (en) 2007-03-14
JP2005530835A (ja) 2005-10-13
ITMI20021392A1 (it) 2003-12-29
KR20060076136A (ko) 2006-07-04
PL206599B1 (pl) 2010-08-31
SI1526839T1 (sl) 2007-08-31
NZ537204A (en) 2006-07-28
EP1526839A1 (en) 2005-05-04
PL374388A1 (en) 2005-10-17
CN1665486A (zh) 2005-09-07
US20060171969A1 (en) 2006-08-03
NO20050347L (no) 2005-01-21
ITMI20021392A0 (it) 2002-06-25
AU2003246564B2 (en) 2008-06-12
IL165601A0 (en) 2006-01-15
CN1319518C (zh) 2007-06-06
PT1526839E (pt) 2007-06-06
RU2004138554A (ru) 2005-08-27
ES2285182T3 (es) 2007-11-16
CA2491152A1 (en) 2003-12-31
DE60312523D1 (de) 2007-04-26
AU2003246564A1 (en) 2004-01-06
DE60312523T2 (de) 2008-01-10
ZA200410109B (en) 2005-09-02
DK1526839T3 (da) 2007-05-21

Similar Documents

Publication Publication Date Title
CN1319518C (zh) 具有改进的生物利用率的液体药物口服药物剂型
CN1208047C (zh) 亲脂性化合物的自体乳化剂
CN1767856A (zh) 用作c型肝炎病毒蛋白酶抑制剂的药物组合物
CN1313080C (zh) 改进的水不溶性药物粒子的制备方法
CN1431896A (zh) 含有高脂溶性药物的油性组合物
CN1292684A (zh) 含有环孢菌素或大环内酯的乳液预浓缩物
CN1527701A (zh) 在口腔中迅速崩解的片剂
CN1251524A (zh) 用于口服给药n-哌啶子基-3-吡唑甲酰胺衍生物、其盐及其溶剂化物的药物组合物
CN1917859A (zh) 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂
CN1518442A (zh) 含有环孢菌素的药物组合物
CN1283229C (zh) 新的自乳化药物释放体系
CN1735401A (zh) 用于不溶于水的抗感冒药物口服给药的微乳浓缩液及其制备方法
CN1094756C (zh) 解热镇痛组合药剂
CN1115150C (zh) 用于治疗偏头痛的含有布洛芬和多潘立酮的药用组合物
CN1208058C (zh) 噁唑烷酮片剂的配方
CN1826110A (zh) 用于口服施用紫杉烷类的半固体制剂
CN1939302A (zh) 西罗莫司药物组合物及制备方法
CN1717219A (zh) 用于联苯二甲双酯口服给药的微乳组合物
CN101052392A (zh) 可口服给药的抗疟药组合制剂及其制备方法
CN1840196A (zh) 一种适用于难溶性药物的分散剂
CN1671421A (zh) 罗西格列酮的包合复合物
CN1849123A (zh) 不受所摄入的食物影响的口服依曲康唑组合物及其制备方法
CN1882594A (zh) 含有稠合吡咯并咔唑的成颗粒组合物
CN1875973A (zh) 一种含n3-邻甲苯甲酰基氟尿嘧啶的药物组合物及其脂质体制剂
CN101035511A (zh) 形成非层状分散体的组合物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110620